Please login to the form below

Three strategies for managing loss of exclusivity successfully

Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.

“Patent losses could sink Allergan”.1

“Drug prices to plummet in wave of expiring patents”.2

“Price decay after loss of brand exclusivity”.3

These are just three headlines that come up when you Google “drug patent expiry”.4

It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices.

However, for society patent expirations are fundamentally a good thing – crucial to maintaining the balance between encouraging innovation and improving opportunities for all.

Loss of exclusivity (LOE) is a natural milestone in a drug’s lifecycle. Focused and effective late lifecycle management can preserve meaningful value for the brand. Kellogg’s Corn Flakes had “generic” competition within a month of its launch more than 100 years ago, and yet it’s still the dominant brand in its market. Having said that, Kellogg’s didn’t face laws and policies that require alternatives to be used over a branded product – this problem is really pharma’s alone.4 With this in mind, just as we do for launch – LOE should be strategically planned for years in advance and carefully managed.

Humalog – Tapping into patient attachment

The history of insulin captures one of the mystifying complexities of the pharmaceutical market — how long-standing drugs become more expensive with time and competition fails to hold down prices.5

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively.6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002.7

In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog.8 Eli Lilly responded by launching an LOE strategy that tapped into patients’ desire for a stable treatment plan.

Patients had years of experience and comfort managing their disease on their current regimen and were resistant to change. Eli Lilly’s messaging focussed on the potential negative impact on adherence should their prescribed treatment change.

RESULT: Humalog is still Lilly’s second top-selling drug with nearly $3 billion in sales in 2018. However, 2019 saw Eli Lilly respond to criticism of high insulin prices by launching a cut-price version.9

Viagra – Over-the-counter switching

Famously developed as a blood pressure treatment, Viagra soon proved to have an unexpected—and highly lucrative—sexual side effect, helping men maintain erections.10 Since FDA approval in 1998 the ‘Little Blue Pill’ had some of the fastest prescription uptakes and sales growth of any medication, bringing in $400 million in revenue in its first quarter after launch and going on to produce annual sales of about $1.8 billion.11

Since losing exclusive rights in 2017, Pfizer undertook an over-the-counter switching strategy to guard against revenue loss. Online sales through Pfizer’s website and health tech start-ups like Roman allow patients to bypass their doctor and buy medication online. In 2017, Pfizer announced it would produce a generic version, called Sildenafil, at half the cost of the brand name. Pfizer are protecting their ‘Little Blue Pill’ brand image with one small, but very significant difference between Viagra and Sildenafil – Sildenafil is white.

RESULT: Pfizer still holds a lead in the erectile dysfunction market even as generics erode sales. Between December 1, 2018 and January 31, 2019, 65% of erectile dysfunction prescriptions filled were for Viagra or its generic version12.

Prilosec – Benchmark for franchise management

AstraZeneca’s patent for its top-selling gastroesophageal reflux disease drug was due to expire in 2001.13They launched a huge effort to transition PRILOSEC patients their newer product NEXIUM. They employed hundreds of new salespeople to detail doctors and hospitals, spent millions on TV and magazine ads and handed out masses of free samples. They tapped into patient and prescriber concerns that transitioning patients from a blockbuster drug like Prilosec to a generic counterpart or other class of drug can cause episodes of patient pain or discomfort.

RESULT: As of 2002, 40% of PRILOSEC patients had switched to NEXIUM, which notched up sales of $3.9 billion in 2004.14 Simultaneous with the switch to NEXIUM, AstraZeneca grew its overall Gastroenterology franchise – by nearly 9% from 2001 to 2002.15

The top three things to consider if you’re approaching LOE:

1) Start the LOE planning process early

Your success will be determined years before LOE actually happens. Share prices tend to take a year to level out after LOE. After this period, the impact of what you do will be far less significant. Ideally start work 4 – 5 years before if you’re factoring in medical and research and development strategies. If you’re deploying purely commercial LOE strategies, 1-2 years in advance may be sufficient.

2) Know what your competitive environment will look like post-LOE

Track all generic entrants and new branded entrants who may reshape the treatment landscape. Do not try and adapt your strategy to be a generic strategy – although price is important and difficult to compete against, don’t fight it. The branded version still has the company perspective and the relational perspective. Instead, maintain face-to-face communication around the time of LOE – when generic competitors enter the market it can be really valuable way to maintain already loyal customers.

3) Understand stakeholder drivers in each market

Generally, there have been shifts in decision making power from the physician to the payer but it’s important to understand the instances where physicians and patients may have decision making power. During the pre-LoE phase, it’s essential to conduct a deep dive into the buying process to understand the key drivers in the prescription flow. Seek opportunities to collaborate with your stakeholders to develop ideas and incentives which meet their specific needs. Don’t forget pharmacists – they are often overlooked but can play a critical role in the buying process.


16th February 2021



Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Blue Latitude Health (UK)
140 Aldersgate Street
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health